Clinical Trials Browser

INDUSTRY × ricolinostat × Plasma cell × Clear all

NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Phase 1/2 Terminated

103 enrolled 21 charts

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

NCT01583283 2022-02-23

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Phase 1 Completed

Disease, Multiple Myeloma, Recurrence, Disease Progression

NCT01323751 2017-04-06

ACY-1215

Phase 1/2 Completed

Multiple Myeloma